39 completed, 10 terminated, 7 unknown, 5 recruiting. 70 Phase 1, 38 Phase 2.
Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2026-02-05 | 2026-09-25 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma Sulfatinib, Etoposide, Isophosphamide - Osteosarcoma | Phase 1 / Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 148 | 2023-01-01 | 2022-10-21 |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Obinutuzumab, Glofitamab, Rituximab - Mature B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 65 | 2022-11-16 | 2026-11-05 |
| A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma Glofitamab, Obinutuzumab, Tocilizumab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Hoffmann-La Roche | 43 | 2022-11-04 | 2025-12-01 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 543 | 2020-11-03 | 2026-11-03 |
| FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma Irinotecan, Actinomycin D, Doxorubicin - Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 1672 | 2020-09-17 | 2024-05-23 |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 | |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents Idelalisib, Rituximab, Ifosfamide - Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma | Phase 1 | Withdrawn | Gilead Sciences | 2019-06-01 | 2018-12-11 | |
| Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors Pazopanib, Ifosfamide, Carboplatin - Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor | Phase 1 / Phase 2 | Unknown | Samsung Medical Center | 46 | 2018-10-01 | 2018-09-19 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2018-06-08 | 2026-10-02 |
| A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Ifosfamide - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 24 | 2017-10-18 | 2020-09-10 |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Venetoclax, Rituximab, Ifosfamide - Diffuse Large B-cell-lymphoma | Phase 1 / Phase 2 | Active not recruiting | Molly Gallogly | 65 | 2017-06-26 | 2022-11-16 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors MASCT-I, Ifosfamide, PD1 antibody - Advanced Solid Tumors | Phase 1 | Terminated | HRYZ Biotech Co. | 105 | 2017-02-22 | 2025-07-24 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer Olaratumab, Doxorubicin, Vincristine - Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 68 | 2016-08-29 | 2020-05-20 |
Showing 20 of 70. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (17) · Sarcoma (13) · Lymphoma (10) · Osteosarcoma (9) · Hodgkin Disease (8) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Lymphoma, Non-Hodgkin (6) · Testicular Neoplasms (6) · Burkitt Lymphoma (5) · Lymphoma, Large-Cell, Anaplastic (5) · Neoplasms (5) · Ovarian Neoplasms (5) · Testicular Germ Cell Tumor (5) · Carcinoma, Renal Cell (4)
Memorial Sloan Kettering Cancer Center (6) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · Children's Oncology Group (2) · Eli Lilly and Company (2) · Hoffmann-La Roche (2) · Samsung Medical Center (2) · St. Jude Children's Research Hospital (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1) · Alaunos Therapeutics (1) · Armando Santoro, MD (1) · BeBetter Med Inc (1)
United States (51) · Italy (9) · France (7) · Spain (6) · United Kingdom (6) · Australia (5) · China (5) · Germany (5) · South Korea (5) · Denmark (4) · Belgium (3) · Canada (3) · Czechia (3) · Netherlands (3) · Israel (2)
Armando Santoro, MD (2) · Sonali Smith (2) · Ajay Gopal (1) · Alba Rubio (1) · Andres Morales, MD (1) · Antonio Casado (1) · Aspasia Stamatoullas Bastard, MD (1) · Benjamin B. Weinberger, MD (1) · Binhao Li, PhD (1) · Burton L. Eisenberg, MD (1)
PMID 31401903, PMID 15814645, PMID 17194908, PMID 19636012, PMID 19994492, PMID 20194867, PMID 23664013, PMID 29226797, PMID 29386196, PMID 29622656, PMID 30518502, PMID 30573564, PMID 30803990, PMID 33035333, PMID 33203665, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34329577, PMID 34416158, PMID 34416160, PMID 34493319, PMID 34515338, PMID 34562750, PMID 35975738, PMID 36821768, PMID 37632592, PMID 38635762, PMID 39240498, PMID 39356980, PMID 39792928, PMID 40920572, PMID 41784015, PMID 41836677, PMID 42545754, PMID 42622258, PMID 42660129
P30CA008748 (2), P30CA033572 (2), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), N01CM62201 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA069533 (1), R01CA136907 (1), U01CA069852 (1), U01CA121947 (1)